Eli Lilly stated on Thursday that it intends to file for regulatory approval of retatrutide, its next-generation obesity treatment, during the first quarter of 2027. The company had previously indicated it might submit an application as early as that year, but determined it requires additional time to compile and verify manufacturing and quality-control data required by regulatory authorities before proceeding with the filing.
The pharmaceutical company reported positive results from two separate Phase 3 clinical trials examining retatrutide as a weekly injection. In one trial, adults with obesity and Type 2 diabetes who received the treatment achieved average weight loss of 20.8%, equivalent to approximately 50 pounds, over 80 weeks. A second trial enrolled adults with severe obesity and established cardiovascular disease, with or without diabetes, who attained average weight loss of 22.6%, or approximately 55.8 pounds, at the same timepoint. Both populations demonstrated improvements in blood sugar measures and reductions in certain cardiovascular risk factors.
Retatrutide functions through a distinct mechanism compared to existing weight loss medications, targeting GLP-1, GIP and glucagon hormones simultaneously, whereas most current treatments target only one or two of these hormones. This mechanism appears to produce more pronounced effects on appetite suppression and food satisfaction. Side effects reported across the trials remained consistent with those observed in earlier studies, with diarrhea, nausea and constipation being the most frequently reported adverse effects, consistent with the broader GLP-1 drug class.
The positive trial results bring the total number of successful late-stage trials for retatrutide to five. Lilly positions the treatment as a key addition to its obesity portfolio, which includes the injection Zepbound and the recently launched pill Foundayo. Analysts have estimated the drug could generate approximately $3.8 billion in sales in 2030, as the company seeks to maintain its market share advantage over competitor Novo Nordisk in what some analysts project could become a $100 billion market segment for weight loss and diabetes treatments by the 2030s.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI